Name | CMS-121 |
Description | CMS-121, a quinolone derivative, is an orally active acetyl-CoA carboxylase 1 (ACC1) inhibitor. CMS-121 protects HT22 cells against ischemia and oxidative damage (EC50: 7 nM and 200 nM). CMS-121 shows strong neuroprotective, antioxidative, anti-inflammatory, and renoprotective activities. |
In vitro | CMS-121 can increase acetyl-CoA in cells. CMS-121 (1 μM; 4 hours; HT22 cells) treatment also increases the phosphorylation of ACC1 at serine 79.[1]. |
In vivo | CMS-121 preserves mitochondrial homeostasis by regulating acetyl-coenzyme A (acetyl-CoA) metabolism. CMS-121 (~20 mg/kg; p.o; daily; for 4 months; female SAMP8 mice) treatment decreases cognitive decline and metabolic and transcriptional markers of aging in the brain when administered to rapidly aging SAMP8 mice. [1]. |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Solubility Information | DMSO : 55 mg/mL (171.14 mM), Sonication is recommended.
|
Keywords | ACC, Acetyl Coenzyme A Carboxylase | CMS 121 | disease | neuroprotective | inhibit | anti-inflammatory | mitochondrial | Alzheimer's | antioxidative | acetylation | Inhibitor | H3K9 | CMS-121 | Acetyl-CoA Carboxylase | dementia | ACC1 |
Inhibitors Related | ND-646 | Olumacostat Glasaretil | PF-05175157 | Haloxyfop | CP-640186 hydrochloride | Firsocostat | PF-05221304 | CP-640186 | Quizalofop-P | Moiramide B | TOFA | Tralkoxydim |
Related Compound Libraries | Bioactive Compound Library | Anti-Obesity Compound Library | Neuroprotective Compound Library | Inhibitor Library | Orally Active Compound Library | Metabolism Compound Library | Lipid Metabolism Compound Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Oxidation-Reduction Compound Library |